Related Experiment Video
Updated: Mar 23, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Sclerostin levels in uremic patients: a link between bone and vascular disease
Annamaria Bruzzese1, Antonio Lacquaniti1, Valeria Cernaro1
1a Department of Clinical and Experimental Medicine , University of Messina , Messina , Italy ;
Abstract:
Sclerostin is a marker of low-turnover bone disease in end stage renal disease patients. The aim of this study was to evaluate serum sclerostin in uremic patients, analyzing its behavior during a single hemodialysis session. Twenty-one adult patients on intermittent hemodialysis treatment were enrolled. Acetate Free Bio-filtration (AFB) was the technique employed. Uremic patients were characterized by higher levels of serum sclerostin when compared with values observed in healthy subjects. Sclerostin assessed in pre-dialysis samples was 1.4 ± 1.02 ng/mL, whereas, in post dialysis samples, a reduction of sclerostin values was observed (0.8 ± 0.6 ng/mL; p: 0.008). Sclerostin correlated with parameters of dialysis adequacy, such as creatinine levels and Kt/V values, and it was significantly associated with atherosclerotic disease. Receiver operating characteristics analysis revealed a good diagnostic profile in identifying atherosclerotic disease. Sclerostin, a full dialyzable substance during AFB dialysis, is closely associated with atherosclerotic disease. Its reduction obtained through AFB could represent a defensive mechanism, improving vascular disease and renal osteodystrophy.
Related Concept Videos
Serum Studies: Renal Function Tests
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease II: Clinical Manifestations
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Skeleton and Calcium Homeostasis

